Clinical significance of perineural invasion by prostate cancer

Published Date: 08 Mar 2023

This study examines the clinical impact of unilateral perineural invasion in prostate cancer. How does unilaterality affect long-term oncology outcomes?

Read Full News

Latest News

HF With Improved Ejection Fraction

Heart Failure with Improved ejection fraction is characterized by previously reduced left ventricular ejection fraction (≤40%) that subsequently improves to >40%. This review highlight existing clinical gaps and proposes future research directions to refine risk stratification and therapeutic approaches for this evolving HF population.

S2 Episode 6: A Futuristic Vision for Treating Myelofibrosis

What will the next decade bring for myelofibrosis care? Drs Jain and Pemmaraju explore futuristic therapies, earlier interventions, and smarter diagnostics.

Radiofrequency Ablation: A First-Line Treatment Option

Drs Kaniksha Desai and Iram Hussain discuss the use of radiofrequency ablation for the treatment of hyperthyroidism.

S2 Episode 5: DNA Repair and Replication Stress in Endometrial Cancer

Drs Ursula A. Matulonis and Joyce F. Liu discuss targeting DNA damage and repair and replication stress in endometrial cancer.

May 09 2025 This Week in Cardiology

The controversial KETO-CTA study, tough decisions in subclinical AF, and another potentially huge benefit for GLP-1 agonist drugs are discussed by John Mandrola, MD, in this week’s podcast.

Should All Newborns Be Screened for Congenital Hypothyroidism?

Drs Kaniksha Desai and Larry Fox discuss congenital hypothyroidism, including when to test and how to treat it.

Todays Updates

Phase 3 REVITALYZ Trial of Once-Nightly Sodium Oxybate in Idiopathic Hypersomnia Finishes Enrollment Marco Meglio

Avadel's REVITALYZ trial for Lumryz in idiopathic hypersomnia shows promise, potentially offering a new treatment option for this underserved condition.

NeurologyLive® Year in Review 2025: Conference Coverage Recap NeurologyLive® Staff

NeurologyLive® provided in-depth coverage of conferences in 2025, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.

Ophthalmology in 2025: Year in Review

Ophthalmology in 2025: Year in Review

Increases in Physician Attrition Rates Could Worsen Shortages

Increases in Physician Attrition Rates Could Worsen Shortages

Hormonal Disorders in 2025: Year in Review

Hormonal Disorders in 2025: Year in Review

Todays Updates

Phase 3 REVITALYZ Trial of Once-Nightly Sodium Oxybate in Idiopathic Hypersomnia Finishes Enrollment Marco Meglio

Avadel's REVITALYZ trial for Lumryz in idiopathic hypersomnia shows promise, potentially offering a new treatment option for this underserved condition.

NeurologyLive® Year in Review 2025: Conference Coverage Recap NeurologyLive® Staff

NeurologyLive® provided in-depth coverage of conferences in 2025, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.

Ophthalmology in 2025: Year in Review

Ophthalmology in 2025: Year in Review

Increases in Physician Attrition Rates Could Worsen Shortages

Increases in Physician Attrition Rates Could Worsen Shortages

Hormonal Disorders in 2025: Year in Review

Hormonal Disorders in 2025: Year in Review

Latest News

Heart Failure with Improved ejection fraction is characterized by previously reduced left ventricular ejection fraction (≤40%) that subsequently improves to >40%. This review highlight existing clinical gaps and proposes future research directions to refine risk stratification and therapeutic approaches for this evolving HF population.

What will the next decade bring for myelofibrosis care? Drs Jain and Pemmaraju explore futuristic therapies, earlier interventions, and smarter diagnostics.

Drs Kaniksha Desai and Iram Hussain discuss the use of radiofrequency ablation for the treatment of hyperthyroidism.

Drs Ursula A. Matulonis and Joyce F. Liu discuss targeting DNA damage and repair and replication stress in endometrial cancer.

The controversial KETO-CTA study, tough decisions in subclinical AF, and another potentially huge benefit for GLP-1 agonist drugs are discussed by John Mandrola, MD, in this week’s podcast.

Drs Kaniksha Desai and Larry Fox discuss congenital hypothyroidism, including when to test and how to treat it.

News All Time

S2 Episode 2: Endometrial Cancer Disparities: Access to Care and Trials

Drs Ursula A. Matulonis and Eloise Chapman-Davis discuss overcoming health disparities in endometrial cancer and increasing clinical trial enrollment of Black women.

S2 Episode 1: Hormonal Therapy Updates in Metastatic Endometrial Cancer

Drs Ursula A. Matulonis and Panagiotis A. Konstantinopoulos discuss hormonal therapy updates and different ways to target and treat ER+ metastatic endometrial cancer.

Managing Familial Hypercholesterolemia in Primary Care

Familial hypercholesterolemia is often diagnosed late, and patients with the condition are significantly undertreated.

IgA Nephropathy: 5 Differential Diagnoses to Know

IgAN diagnosis is complex, and differentiation from other glomerulopathies is critical. Consider these five important differentials to ensure timely diagnosis and appropriate treatment.

Q&A: Are You Sure the Diagnosis Is IgA Nephropathy?

Arnold B. Alper, MD, discusses the IgA nephropathy differential diagnosis.

SABCS 2024: New Treatment Options in HR+/HER2- Breast Cancer

Dr Avan Armaghani discusses the clinical impact of several studies presented at SABCS.

Key Updates in Early Breast Cancer From SABCS 2024

Key updates from SABCS 2024 in early breast cancer include the COMET study on DCIS recurrence, INSEMA trial on SLNB omission, and OlympiA updates on adjuvant olaparib, shared by Dr Harold Burstein.

More Than Hives: Discussing Chronic Spontaneous Urticaria

Dermatologists discuss common roadblocks in communicating with patients with chronic spontaneous urticaria, who often search for a cause they can fix for a condition lacking in community resources.

Cardiac Myosin Inhibitors: Is the Emperor Wearing Any Clothes?

A commentary on the need for better trials and long-term data for the myosin inhibitors aficamten and mavacamten in obstructive hypertrophic cardiomyopathy.

New Directions in Anemia and Related Disorders From ASH 2024

Strategies to reduce disease burden in alpha- or beta-thalassemia, sickle cell disease, and polycythemia vera, and insights into anemia in IBD, are among anemia highlights from ASH 2024.

Episode 6: HER2-Ultra-Low Breast Cancer

Drs Kathy Miller and Francisco J. Esteva discuss testing and therapeutic options for the new classification of HER2-ultra-low breast cancer.

Growth Hormone and the Thyroid Gland: A Complex Relationship

Drs Kaniksha Desai and Laurence Katznelson discuss the complex relationship between growth hormone and the thyroid gland.

ACR 2024: Key Insights on Updated Lupus Nephritis Guidelines

Dr Bella Mehta reviews new guidance on frequent monitoring, triple therapy, early biopsy, and reduced steroids for better outcomes.

Episode 5: Sequencing of ADCs for Metastatic HER2-Low Disease

Kathy D. Miller, MD, and Stephanie L. Graff, MD, discuss sequencing of ADCs for metastatic HER2-low breast cancer including sequencing, toxicities, and clinical trials.

Glomerular Disease Highlights From ASN Kidney Week 2024

Glomerular disease highlights from ASN 2024 include data on atacicept benefits in IgA nephropathy, protein reduction from pegcetacoplan, and a possible new therapy for membranous nephropathy.

Thrombocytosis and Cancer Risk: Management in Primary Care

Dr Kevin Fernando discusses managing thrombocytosis and the risk for cancer in primary care.

Recommended News For You

Cancer deaths expected to rise to over 18 million in 2050, nearly 75% more than in 2024

Breast cancer prevention: How nurse practitioners and physician assistants can help

Is It Really Cancer? More Concerns About Accelerated Approval; Metformin and Cancer

Recently released national data on drug use and abuse among Americans.

FDA Authorizes Three Different Uses for Injectable Antibiotic.

Weight loss trial reports success for breast cancer patients at one year mark

Researchers use AI to monitor side effects of chemotherapy and support families dealing with pediatric cancer.

Recommended Articles For You

What Is May-Hegglin Anomaly? Understanding this Rare Blood Disorder 

The Benefits and Risks of Thrombolytics: A Comprehensive Guide  

Red Blood Cell Microparticles: Tiny Warriors Against Bleeding in the Brain 

The Mystery of Carotid Body Tumors: The Facts You Need to Know 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Mouse study finds tirzepatide slowed obesity-associated breast cancer growth

2.

AI is useful in low-resource areas for triaging breast masses.

3.

Q&A: Researchers discuss identifying potential new protein targets for melanoma therapeutics

4.

When performed by skilled surgeons, robotic surgery for pancreatic tumors is safe and feasible.

5.

Financial hardship common in patients with cancer

1.

The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring

2.

New Frontiers in Diagnosing and Managing Myelodysplastic Syndromes (MASLD)

3.

Inside Oncology Trials: From Protocol to Progress in Cancer Research and Care

4.

Is AI The New Radiologist For Breast MRI?

5.

Navigating the Unknown: How to Cope with Anaplastic Thyroid Cancer

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months

2.

Updates on the First Line Management of ALK+ NSCLC

3.

Efficient Management of First line ALK-rearranged NSCLC - Part VI

4.

Efficient Management of First line ALK-rearranged NSCLC

5.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot